No. But Novo Nordisk owns eleven invented names it could use for a weight-loss drug, and it bought the matching web address for only six of them. One of the six is Wegovamy.
CagriSema brand name, checked September 4, 2026: not announced · FDA approved: No · US decision: expected Q4 2026 · US price: not announced.
I built a daily watch on Lilly’s filings while reporting retatrutide’s brand name, so this week I pointed it at Novo Nordisk. Novo has been filing invented names since 2024, and it bought the domain for one of them two days after filing.
Does CagriSema have a brand name yet?
No. Novo has not announced one, and CagriSema is not a brand. It is a portmanteau of the two ingredients, cagrilintide and semaglutide. Novo has told investors to expect an FDA decision in the fourth quarter of 2026, so the name should be public within months. The generic name will not change: cagrilintide plus semaglutide, the Wegovy molecule.
Novo has eleven invented words on file and alive at the US Patent and Trademark Office, all in Class 005, the pharmaceutical class, all listing weight loss: Anuetake, Glemway, Plosbrio, Zicouras, Omrifio, Coureli, Zarjoty, Semditu, Axessovo, Ayonzilo and Wegovamy. It also registered Wegovy+ and Wegovy Plus this summer, on August 25 and September 1.
Nothing in the records ties any of them to CagriSema, and a company this size files names it never uses. The goods lists cannot narrow it either. Wegovamy’s is word for word identical to the Wegovy refiling Novo made six weeks earlier, down to alcohol dependence and Alzheimer’s disease, which is franchise boilerplate rather than a description of any one product. The class that would have to name a disease is Class 044, medical information services. Novo has not filed any of these names there.
Get the next one in your inbox
I cover the latest GLP-1 trials and access changes weekly. Free, no spam, unsubscribe whenever.
Is Wegovamy CagriSema’s brand name?
The company has not confirmed it. But Novo bought the domain for six of the eleven names, and Wegovamy is one.
Novo’s own site is registered through CSC Corporate Domains and runs on nameservers inside novonordisk.com. Registrant names are redacted on new domains, so that pairing is what I match on. Six of the eleven match it: anuetake.com and glemway.com, registered in September 2024; zicouras.com and omrifio.com in September 2025; wegovamy.com this April; and coureli.com two weeks after that. None of the six resolves to a server. Nothing is there, which is what a held name looks like whether it is being kept for a launch or kept off the market.
The Wegovamy dates are the tightest. Novo filed the trademark abroad on April 22, 2026, bought wegovamy.com on April 24, extended it to the United States on May 20, and on September 1 the application was published for opposition, the stage where a rival can object. Two days from the name being filed to the address being bought. Novo does that with most of the names it means to keep, though, so the speed alone does not single Wegovamy out.
Then there is the word. Wegovamy reads as Wegovy plus amy, and CagriSema is semaglutide, the molecule sold as Wegovy, plus cagrilintide, an amylin analogue. Amylin is a hormone your pancreas releases alongside insulin, and cagrilintide is a long-acting analogue of it. The letters line up with the ingredients, which is an observation about the word and not something Novo has said.
I would still not call it a decision. Companies abandon names they have registered, and the FDA reviews the proposed brand name separately from the drug and turns down names it thinks patients or pharmacists could mix up. Wegovamy borrows most of its letters from a drug already on the shelf, so that one is a real problem.
There is a decent case for Wegovy+ instead. Novo filed it in Denmark a month before it filed CagriSema with the FDA, and it registered in August. Novo also has to name several other drugs right now: its own quarterly report puts two zenagamtide trials, a high-dose cagrilintide trial and an oral semaglutide decision in the same few months, and any of the six addresses could belong to one of those.
The names Novo did not buy the address for
The other four were registered by somebody else, and quickly. Zarjoty, Semditu, Axessovo and Ayonzilo were filed in the United States on February 25, 2026. All four .coms went on February 27, two days later, through Unstoppable Domains, and all four sit on the same parking service. The one I opened offers the name for sale. RDAP does not say who registered them.
The same parking service holds wegovyplus.com, which resolves to the same two IP addresses. Novo does not have that one either. It was registered on November 20, 2025, the day the two Wegovy+ applications went in, and it is parked for sale now. So the obvious guess is a name Novo has registered as a trademark and does not hold the domain for.
| Name | US trademark filed | The matching .com |
|---|---|---|
| Anuetake, Glemway | Oct 15, 2024 | Matches Novo’s fingerprint, Sept 5, 2024 |
| Plosbrio | Jun 20, 2025 | Still unregistered |
| Zicouras, Omrifio | Oct 15, 2025 | Matches Novo’s fingerprint, Sept 23, 2025 |
| Coureli | Oct 15, 2025 | Matches Novo’s fingerprint, May 7, 2026 |
| Wegovy+, Wegovy Plus | Nov 20, 2025 | wegovyplus.com registered elsewhere the same day, parked for sale |
| Zarjoty, Semditu, Axessovo, Ayonzilo | Feb 25, 2026 | Registered elsewhere two days later, all four parked |
| Wegovamy | May 20, 2026 | Matches Novo’s fingerprint, Apr 24, 2026 |
What would settle it
Two documents would: an announcement from Novo, which usually comes at or near approval, or the FDA approval letter, which carries the proprietary name on the front page. One of these words turning up in Class 044 with a disease written next to it would narrow the field without naming the drug.
I checked what Lilly did before Zepbound. It registered zepbound.com on April 13, 2022, filed the trademark the next day, and the drug was approved nineteen months later under that name. The order there is the reverse of Wegovamy’s, and it is the order Novo used for Anuetake and Glemway, whose addresses were bought six weeks before those names were filed. What the two companies have in common is that the address and the paperwork move together. It is a clue and not a rule: Lilly filed eight other zep names between 2020 and 2021 and every one of them is dead.
One thing in the file I cannot read at all. On the day Novo filed Wegovy+ in Denmark it also filed three logos, one described in full as “a single vertical wavy band,” for diabetes and weight loss. I have no idea whether that is packaging, a pen or nothing.
My read is that Novo has already picked something. You do not file a name abroad, buy the domain inside 48 hours and extend it to the US Patent and Trademark Office for a name still on a whiteboard. That reasoning covers all six names Novo bought domains for, and only one can be CagriSema. My bet is Wegovamy, on the letters. If it is wrong, it will be because the FDA turned the name down or because Novo is holding it for something else. I check these filings daily and this page changes the day the CagriSema brand name is announced, at the same address.
For how CagriSema actually performed against tirzepatide, which is the more useful question, see CagriSema vs Zepbound.